SEQUENCE LISTING

<110> INNATE PHARMA S.A.S.
UNIVERSITA DI GENOVA

<120> "Novel triggering receptor involved in natural cytotoxicity mediated by human Natural Killer cells and antibodies that identify the same"

<130> SEQ-FR-1060

<140>
<141>

<160> 13

<170> PatentIn Ver. 2.1

<210> 1
<211> 674
<212> DNA
<213> Human NK cell

<400> 1
ccttcctcct ccacccagac ctcactgctc agatcccctt cgccaactgg gacatcttcc 60
gacatggcct ggatgctgtt gctcatcttg atcatggtcc atccaggatc ctgtgctctc 120
tgggtgtccc agccccctga gattcgtacc ctggaaggat cctctgcctt cctgccctgc 180
tccttcaatg ccagccaagg gagactggcc attggctccg tcacgtggtt ccgagatgag 240
gtggttccag ggaaggaggt gaggaatgga accccagagt tcaggggccg cctggcccca 300
cttgcttctt cccgtttcct ccatgaccac caggctgagc tgcacatccg ggacgtgcga 360
ggccatgacg ccagcatcta cgtgtgcaga gtggaggtgc tgggccttgg tgtcgggaca 420
gggaatggga ctcggctggt ggtggagaaa gaacatcctc agctaggggc tggtacagtc 480
ctcctccttc gggctggatt ctatgctgtc agctttctct ctgtggccgt gggcagcacc 540
gtctattacc agggcaaatg ccactgtcac atgggaacac actgccactc ctcagatggg 600
ccccgaggrg tgattccaga gcccagatgt ccctagtcct cttcaaaaga ccccaataaa 660
tctgccccac cact 674

<210> 2
<211> 190
<212> PRT
<213> Human NK cell

<400> 2
Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser
1 5 10 15

Cys Ala Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly
20 25 30

Ser Ser Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu
35 40 45

Ala Ile Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys
50 55 60

Glu Val Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu
65 70 75 80

Ala Ser Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg
85 90 95

Asp Val Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val
100 105 110

Leu Gly Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu
115 120 125

```
Lys Glu His Pro Gln Leu Gly Ala Gly Thr Val Leu Leu Leu Arg Ala
    130                 135                 140

Gly Phe Tyr Ala Val Ser Phe Leu Ser Val Ala Val Gly Ser Thr Val
145                 150                 155                 160

Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His Cys His Ser
                165                 170                 175

Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys Pro
            180                 185                 190


<210> 3
<211> 18
<212> PRT
<213> Human NK cell

<400> 3
Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser
  1               5                  10                  15

Cys Ala



<210> 4
<211> 120
<212> PRT
<213> Human NK cell

<400> 4
Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser
  1               5                  10                  15

Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile
             20                  25                  30

Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val
         35                  40                  45

Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser
     50                  55                  60

Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val
 65                  70                  75                  80

Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val Leu Gly
                85                  90                  95

Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu Lys Glu
            100                 105                 110

His Pro Gln Leu Gly Ala Gly Thr
        115                 120


<210> 5
<211> 19
<212> PRT
<213> Human NK cell

<400> 5
Val Leu Leu Leu Arg Ala Gly Phe Tyr Ala Val Ser Phe Leu Ser Val
  1               5                  10                  15

Ala Val Gly
```

<210> 6
<211> 33
<212> PRT
<213> Human NK cell

<400> 6
Ser Thr Val Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His
1 5 10 15

Cys His Ser Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys
20 25 30

Pro

<210> 7
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:peptide derived from natural sequence, useful for antiserum production

<400> 7
Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Cys
1 5 10 15

<210> 8
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: up primer for NKp30 cDNA probe of for NKp30 cDNA amplification

<400> 8
cagggcatct cgagtttccg acatggcctg gatgctgttg 40

<210> 9
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:down primer for NKp30 cDNA probe amplification

<400> 9
gactaggatc cgcatgtgta ccagccccta gctgaggatg 40

<210> 10
<211> 421
<212> DNA
<213> Human NK cell

<400> 10
ttccgacatg gcctggatgc tgttgctcat cttgatcatg gtccatccag gatcctgtgc 60
tctctgggtg tcccagcccc ctgagattcg taccctggaa ggatcctctg ccttcctgcc 120
ctgctccttc aatgccagcc aagggagact ggccattggc tccgtcacgt ggttccgaga 180

tgaggtggtt ccagggaagg aggtgaggaa tggaacccca gagttcaggg gccgcctggc 240
cccacttgct tcttcccgtt tcctccatga ccaccaggct gagctgcaca tccgggacgt 300
gcgaggccat gacgccagca tctacgtgtg cagagtggag gtgctgggcc ttggtgtcgg 360
gacagggaat gggactcggc tggtggtgga gaaagaacat cctcagctag gggctggtac 420
a 421

<210> 11
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:down primer for
NKp30 cDNA amplification

<400> 11
gatttattgg ggtcttttga ag 22

<210> 12
<211> 606
<212> DNA
<213> Human NK cell

<400> 12
ttccgacatg gcctggatgc tgttgctcat cttgatcatg gtccatccag gatcctgtgc 60
tctctgggtg tcccagcccc ctgagattcg taccctggaa ggatcctctg ccttcctgcc 120
ctgctccttc aatgccagcc aagggagact ggccattggc tccgtcacgt ggttccgaga 180
tgaggtggtt ccagggaagg aggtgaggaa tggaacccca gagttcaggg gccgcctggc 240
cccacttgct tcttcccgtt tcctccatga ccaccaggct gagctgcaca tccgggacgt 300
gcgaggccat gacgccagca tctacgtgtg cagagtggag gtgctgggcc ttggtgtcgg 360
gacagggaat gggactcggc tggtggtgga gaaagaacat cctcagctag gggctggtac 420
agtcctcctc cttcgggctg gattctatgc tgtcagcttt ctctctgtgg ccgtgggcag 480
caccgtctat taccagggca aatgccactg tcacatggga acacactgcc actcctcaga 540
tgggccccga ggrgtgattc cagagcccag atgtccctag tcctcttcaa aagaccccaa 600
taaatc 606

<210> 13
<211> 573
<212> DNA
<213> Human NK cell

<400> 13
atggcctgga tgctgttgct catcttgatc atggtccatc caggatcctg tgctctctgg 60
gtgtcccagc cccctgagat tcgtaccctg gaaggatcct ctgccttcct gccctgctcc 120
ttcaatgcca gccaagggag actggccatt ggctccgtca cgtggttccg agatgaggtg 180
gttccaggga aggaggtgag gaatggaacc ccagagttca ggggccgcct ggccccactt 240
gcttcttccc gtttcctcca tgaccaccag gctgagctgc acatccggga cgtgcgaggc 300
catgacgcca gcatctacgt gtgcagagtg gaggtgctgg gccttggtgt cgggacaggg 360
aatgggactc ggctggtggt ggagaaagaa catcctcagc taggggctgg tacagtcctc 420
ctccttcggg ctggattcta tgctgtcagc tttctctctg tggccgtggg cagcaccgtc 480
tattaccagg gcaaatgcca ctgtcacatg ggaacacact gccactcctc agatgggccc 540
cgaggrgtga ttccagagcc cagatgtccc tag 573

SEQUENCE LISTING

<110> INNATE PHARMA S.A.
UNIVERSITA DI GENOVA

<120> "Novel triggering receptor involved in natural cytotoxicity mediated by human Natural Killer cells and antibodies that identify the same"

<130> SEQ-FR-1060

<140>
<141>

<160> 13

<170> PatentIn Ver. 2.1

<210> 1
<211> 674
<212> DNA
<213> Human NK cell

<400> 1
ccttcctcct ccacccagac ctcactgctc agatcccctt cgccaactgg gacatcttcc 60
gacatggcct ggatgctgtt gctcatcttg atcatggtcc atccaggatc ctgtgctctc 120
tgggtgtccc agccccctga gattcgtacc ctggaaggat cctctgcctt cctgccctgc 180
tccttcaatg ccagccaagg gagactggcc attggctccg tcacgtggtt ccgagatgag 240
gtggttccag ggaaggaggt gaggaatgga accccagagt tcaggggccg cctggcccca 300
cttgcttctt cccgtttcct ccatgaccac caggctgagc tgcacatccg ggacgtgcga 360
ggccatgacg ccagcatcta cgtgtgcaga gtggaggtgc tgggccttgg tgtcgggaca 420
gggaatggga ctcggctggt ggtggagaaa gaacatcctc agctaggggc tggtacagtc 480
ctcctccttc gggctggatt ctatgctgtc agctttctct ctgtggccgt gggcagcacc 540
gtctattacc agggcaaatg ccactgtcac atgggaacac actgccactc ctcagatggg 600
ccccgaggrg tgattccaga gcccagatgt ccctagtcct cttcaaaaga ccccaataaa 660
tctgccccac cact 674

<210> 2
<211> 190
<212> PRT
<213> Human NK cell

<400> 2
Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser
1 5 10 15

Cys Ala Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly
20 25 30

```
Ser Ser Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu
         35                  40                  45

Ala Ile Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys
     50                  55                  60

Glu Val Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu
 65                  70                  75                  80

Ala Ser Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg
                 85                  90                  95

Asp Val Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val
            100                 105                 110

Leu Gly Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu
        115                 120                 125

Lys Glu His Pro Gln Leu Gly Ala Gly Thr Val Leu Leu Leu Arg Ala
    130                 135                 140

Gly Phe Tyr Ala Val Ser Phe Leu Ser Val Ala Val Gly Ser Thr Val
145                 150                 155                 160

Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His Cys His Ser
                165                 170                 175

Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys Pro
            180                 185                 190
```

<210> 3
<211> 18
<212> PRT
<213> Human NK cell

<400> 3

```
Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser
  1               5                  10                  15

Cys Ala
```

<210> 4
<211> 120
<212> PRT

<213> Human NK cell

<400> 4

```
Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser
 1               5                  10                  15

Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile
            20                  25                  30

Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val
        35                  40                  45

Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser
    50                  55                  60

Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val
65                  70                  75                  80

Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val Leu Gly
                85                  90                  95

Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu Lys Glu
            100                 105                 110

His Pro Gln Leu Gly Ala Gly Thr
        115                 120
```

<210> 5
<211> 19
<212> PRT
<213> Human NK cell

<400> 5

```
Val Leu Leu Leu Arg Ala Gly Phe Tyr Ala Val Ser Phe Leu Ser Val
 1               5                  10                  15

Ala Val Gly
```

<210> 6
<211> 33
<212> PRT
<213> Human NK cell

<400> 6

```
Ser Thr Val Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His
```

1 5 10 15

Cys His Ser Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys
20 25 30

Pro

<210> 7
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:peptide derived from natural sequence, useful for antiserum production

<400> 7
Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Cys
1 5 10 15

<210> 8
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: up primer for NKp30 cDNA probe of for NKp30 cDNA amplification

<400> 8
cagggcatct cgagtttccg acatggcctg gatgctgttg 40

<210> 9
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:down primer for NKp30 cDNA probe amplification

<400> 9
gactaggatc cgcatgtgta ccagccccta gctgaggatg 40

<210> 10
<211> 421
<212> DNA
<213> Human NK cell

<400> 10
ttccgacatg gcctggatgc tgttgctcat cttgatcatg gtccatccag gatcctgtgc 60
tctctgggtg tcccagcccc ctgagattcg taccctggaa ggatcctctg ccttcctgcc 120
ctgctccttc aatgccagcc aagggagact ggccattggc tccgtcacgt ggttccgaga 180
tgaggtggtt ccagggaagg aggtgaggaa tggaacccca gagttcaggg gccgcctggc 240
cccacttgct tcttcccgtt tcctccatga ccaccaggct gagctgcaca tccgggacgt 300
gcgaggccat gacgccagca tctacgtgtg cagagtggag gtgctgggcc ttggtgtcgg 360
gacagggaat gggactcggc tggtggtgga gaaagaacat cctcagctag gggctggtac 420
a 421

<210> 11
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:down primer for
NKp30 cDNA amplification

<400> 11
gatttattgg ggtcttttga ag 22

<210> 12
<211> 606
<212> DNA
<213> Human NK cell

<400> 12
ttccgacatg gcctggatgc tgttgctcat cttgatcatg gtccatccag gatcctgtgc 60
tctctgggtg tcccagcccc ctgagattcg taccctggaa ggatcctctg ccttcctgcc 120
ctgctccttc aatgccagcc aagggagact ggccattggc tccgtcacgt ggttccgaga 180
tgaggtggtt ccagggaagg aggtgaggaa tggaacccca gagttcaggg gccgcctggc 240
cccacttgct tcttcccgtt tcctccatga ccaccaggct gagctgcaca tccgggacgt 300
gcgaggccat gacgccagca tctacgtgtg cagagtggag gtgctgggcc ttggtgtcgg 360
gacagggaat gggactcggc tggtggtgga gaaagaacat cctcagctag gggctggtac 420
agtcctcctc cttcgggctg gattctatgc tgtcagcttt ctctctgtgg ccgtgggcag 480
caccgtctat taccagggca aatgccactg tcacatggga acacactgcc actcctcaga 540
tgggccccga ggrgtgattc cagagcccag atgtccctag tcctcttcaa aagaccccaa 600
taaatc 606

<210> 13
<211> 573
<212> DNA

<213> Human NK cell

<400> 13

atggcctgga tgctgttgct catcttgatc atggtccatc caggatcctg tgctctctgg 60
gtgtcccagc cccctgagat tcgtaccctg gaaggatcct ctgccttcct gccctgctcc 120
ttcaatgcca gccaagggag actggccatt ggctccgtca cgtggttccg agatgaggtg 180
gttccaggga aggaggtgag gaatggaacc ccagagttca ggggccgcct ggccccactt 240
gcttcttccc gtttcctcca tgaccaccag gctgagctgc acatccggga cgtgcgaggc 300
catgacgcca gcatctacgt gtgcagagtg gaggtgctgg gccttggtgt cgggacaggg 360
aatgggactc ggctggtggt ggagaaagaa catcctcagc taggggctgg tacagtcctc 420
ctccttcggg ctggattcta tgctgtcagc tttctctctg tggccgtggg cagcaccgtc 480
tattaccagg gcaaatgcca ctgtcacatg ggaacacact gccactcctc agatgggccc 540
cgaggrgtga ttccagagcc cagatgtccc tag 573